ACOG
Alpha Cognition Soars in Q4: Commercial Launch Progress and Payer Access Drive Growth
In a major milestone, Alpha Cognition has reported continued sales growth and ongoing demand expansion of its flagship product, ZUNVEYL, which is the first new oral Alzheimer's treatment approved in more than 15 years. According to Michael McFadden, Chief Executive Officer of Alpha Cognition, the company's